Longterm safety of rituximab: Final report of the rheumatoid arthritis global clinical trial program over 11 years

Journal of Rheumatology

Volumn 42, Issue 10, 2015, Pages 1761-1766

  Van Vollenhoven, Ronald F ^a   Fleischmann, Roy M ^b   Furst, Daniel E ^c   Lacey, Stuart ^d   Lehane, Patricia B ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d Roche Products Ltd   (United States)

Author keywords

Rheumatoid arthritis; Rituximab; Safety

Indexed keywords

ABATACEPT; IMMUNOGLOBULIN; METHOTREXATE; PLACEBO; RITUXIMAB; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR INHIBITOR; MONOCLONAL ANTIBODY;

ARTICLE; ATYPICAL MYCOBACTERIOSIS; BENIGN TUMOR; BREAST CANCER; CANCER RISK; CONNECTIVE TISSUE DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; FALLING; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HEPATITIS B; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; INFUSION RELATED REACTION; LONG TERM CARE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIDRUG RESISTANT TUBERCULOSIS; MUSCULOSKELETAL DISEASE; OPEN STUDY; OPPORTUNISTIC INFECTION; OSTEOARTHRITIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SIDE EFFECT; SOLID TUMOR; ADULT; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; HEALTH; MIDDLE AGED; PATIENT SAFETY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLOBAL HEALTH; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; RITUXIMAB; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84943234492     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.150051     Document Type: Article

References (15)

1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
2. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-21.
3. van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013;72:1496-502.
4. Loveless J, Olech E, Pritchard CH, Chai A, Kelman A, Klearman M. An open-label, prospective study (SUNDIAL) of the safety of rituximab in combination with disease-modifying anti-rheumatic drugs in patients with active rheumatoid arthritis (SUNDIAL). Arthritis Rheum 2009;60 Suppl 10:1660.
5. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
6. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908.
7. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 2010;69:1629-35.
8. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, et al; IMAGE Investigators. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46.
9. Centers for Disease Control and Prevention. National Vital Statistics Reports. Deaths: final data for 2005. [Internet. Accessed June 30, 2015.] Available from: www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56-10.pdf
10. Dixon WG, Watson KD, Lunt M, Hyrich KL; British Society for Rheumatology Biologics Register Control Centre Consortium, Silman AJ, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12.
11. Mellemkjaer L, Linet MS, Gridley G, Frisch M, Møller H, Olsen JH. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-7.
12. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95.
13. National Cancer Institute. Surveillance, epidemiology, and end results. [Internet. Accessed June 30, 2015.] Available from: seer.cancer.gov
14. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R45.
15. Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum 2009;60:3225-8.